Undertreatment of Neutropenia
Patients younger than 65 years who have non-Hodgkin lymphoma (NHL) are less likely to receive prophylactic treatment for grade 3 and 4 neutropenia.
In a study in which 1,570 patients with NHL were enrolled, it was found that there were disparities in the way granulocyte colony-stimulating factor (G-CSF) was administered. While all patients received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), those in the younger age group (65 years and under, 54%) were less likely to receive G-CSF with their chemotherapy as a preventive measure than those in the older age group (65 years and older, 45.9%). For more information, click here.